Các tập đoàn dược phẩm chi hàng tỉ USD để khai thác dịch vụ chăm sóc sức khỏe tại Trung Quốc

-----

More than half of the world’s top 20 pharmaceutical companies by revenue are attending the fourth China International Import Expo (CIIE) in Shanghai this week, as they look to cement their positions in the Chinese market.

China’s health needs are set to grow rapidly over the next decade. The country has one of the world’s fastest-aging societies and has seen significant rises in the prevalence of obesity (béo phì) and a range of chronic diseases (bệnh mạn tính) in recent years.

...Sanofi, the French pharmaceutical giant, is exhibiting at the expo for the fourth consecutive year. In 2021, the firm is promoting 20 newly developed products and health solutions aligned with China’s most urgent medical needs, including vaccines and treatments for rare and chronic diseases.

The company also sees growing opportunities in digital health care (chăm sóc sức khỏe số). Sanofi recently teamed up with JD Health — one of the biggest Chinese players in the industry — to develop new solutions related to online diagnostics and treatment.

...German drug maker Bayer — also attending CIIE for the fourth time — is exhibiting several new cancer treatments (chữa trị ung thư), as well as solutions for managing diabetes and promoting cardiovascular, digestive tract, and scalp health. It also launched a new intestinal health product developed in partnership with two Chinese entities — Jiangnan University and Wecare Probiotics, both based in the eastern Jiangsu province.

Japan’s Takeda, meanwhile, says it aims to begin marketing more than 15 new drugs in China by 2025, benefitting over 10 million patients.

Bài trước: Trung Quốc đẩy mạnh việc bảo vệ các di tích văn hóa cổ